Kimberly Leonard (@leonardkl) is a member of AHCJ’s Right to Know Committee and co-chair of the Washington, D.C., chapter. She covers Congress, the White House, and the Department of Health and Human Services as a health care reporter for the Washington Examiner.
Photo: Ryan Basen Baltimore Health Commissioner Leana Wen, right, helps demonstrate how naloxone is administered.
Health journalists in Washington, D.C., participated in an all-day training session about reporting on the opioid crisis, hearing from treatment experts, medical providers and public health advocates.
The event took place Feb. 23 at the University of Maryland’s Philip Merrill College of Journalism, and was a partnership between the D.C. chapter of the Association of Health Care Journalists and the National Press Foundation. Continue reading →
Dr. Michael A. Carome, M.D., is the director of Public Citizen’s Health Research Group. He is an expert on issues of drug and medical device safety, pharmacy compounding, Food and Drug Administration oversight, health care policy, and the protection of human research subjects.
In honor of Sunshine Week, AHCJ invited organizations devoted to government transparency to write about how their work can help health care reporters. Here is the second of four.
Public Citizen’s Health Research Group today released an updated report cataloging all major financial settlements that the pharmaceutical industry has been forced to sign with federal and state governments from 1991 through 2017 for illegal activities.
The report shows a dramatic decrease since 2013 in both the total amount paid and the average penalty. Additionally, it found that state governments have virtually stopped prosecuting pharmaceutical manufacturers on their own initiative and with their own resources. Continue reading →
Sibyl Wilmont is a second-career registered nurse and clinical researcher with more than 25 years of experience in health care journalism, patient advocacy, pharmaceutical/biotech PR, and academic medical communications.
Taken at face value, Right-to-Try (RTT) legislation sounds like a no-brainer, promising to improve access to treatments yet unapproved for marketing by the FDA for people with terminal illnesses. But it’s not that simple, according to Alison Bateman-House, Ph.D., M.P.H., M.A., an ethicist and assistant professor at the New York University School of Medicine.
In fact, many of its basic provisions make it unlikely to deliver on its promise. At a New York City Metro AHCJ Chapter meeting in November, she discussed reasons for her argument that RTT will only serve to limit, rather than expand, access to potentially life-saving treatments. Continue reading →
Liz Seegert (@lseegert), is AHCJ’s topic editor on aging. Her work has appeared in NextAvenue.com, Journal of Active Aging, Cancer Today, Kaiser Health News, the Connecticut Health I-Team and other outlets. She is a senior fellow at the Center for Health Policy and Media Engagement at George Washington University and co-produces the HealthCetera podcast.
The death of musician Glen Campbell on Aug. 8 after a very public struggle with Alzheimer’s disease has again focused attention on whether science will ever find a drug that truly halts this devastating condition.
Deaths from Alzheimer’s are increasing, according to the nonprofit advocacy group UsAgainstAlzheimer’s. The organization, which has the goal of stopping Alzheimer’s by 2020, lobbies legislators to increase research funding. Some 35 drugs are in various phases of clinical trials. But as this excellent Pacific Standard article reports, the goal of a cure by 2020, or 2025, is iffy at best. Continue reading →
President Donald Trump has spoken about the cost of drugs frequently. Though not always clearly and consistently, he has called for government negotiation of prices. Drug prices also have caught Congress’s eye, although we’re not quite sure what (if anything) legislators are willing to do about it.